Trials / Sponsors / Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Academic / Other · 12 registered clinical trials.

Status	Trial	Phase	Started
Completed	Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk M Myelodysplastic Syndromes	Phase 2	2015-05-21
Unknown	National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL	—	2014-07-01
Terminated	Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines Ovarian Cancer	Phase 2	2014-02-01
Completed	PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)	Phase 2	2011-11-01
Terminated	SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment Colorectal Carcinoma	Phase 2	2011-08-01
Terminated	Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant	Phase 1 / Phase 2	2010-11-01
Completed	Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Chronic Myelogenous Leukemia (CML)	Phase 4	2010-10-01
Completed	Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment Metastatic Breast Cancer	Phase 2	2010-07-01
Completed	Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring S Myelodysplastic Syndromes	Phase 2	2010-03-26
Completed	Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma Multiple Myeloma	Phase 3	2010-03-01
Completed	Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidom Multiple Myeloma	Phase 1 / Phase 2	2009-11-01
Completed	Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma Multiple Myeloma	Phase 3	2009-04-01